Table 2.
Survey 1 | Survey 2 | Survey 3 | p-Value | |
---|---|---|---|---|
n = 4124 | n = 4703 | n = 4543 | ||
(April 2020) | (July 2020) | (Jan 2021) | ||
Sociodemographic characteristics: n (%) | ||||
Age group | <0.001 | |||
18–20 years | 1455 (35.3%) | 1506 (32.0%) | 1617 (35.6%) | |
21–30 years | 2456 (59.6%) | 2786 (59.2%) | 2551 (56.2%) | |
31–40 years | 158 (3.8%) | 297 (6.3%) | 262 (5.8%) | |
41–50 years | 20 (0.5%) | 65 (1.4%) | 64 (1.4%) | |
51–60 years | 28 (0.7%) | 32 (0.67%) | 39 (0.9%) | |
61 years and above | 7 (0.2%) | 17 (0.4%) | 10 (0.2%) | |
Gender | 0.004 | |||
Male | 2490 (60.5%) | 2768 (59.1%) | 2837 (62.4%) | |
Female | 1626 (39.5%) | 1916 (40.9%) | 1706 (37.6%) | |
COVID-19 preventive measures: n (%) | ||||
Mask use | 2112 (51.2%) | 2644 (56.2%) | 2371 (52.2%) | <0.001 |
Observe 1.5 m physical distancing | 2634 (63.9%) | 2781 (59.1%) | 2602 (57.3%) | <0.001 |
Wash hands regularly with soap | 3334 (80.8%) | 3491 (74.2%) | 3560 (78.4%) | <0.001 |
Use alcohol-based hand gel regularly | 2352 (57.0%) | 2687 (57.1%) | 2850 (62.7%) | <0.001 |
Cover mouth when coughing/sneezing | 3606 (87.4%) | 3875 (82.4%) | 3937 (86.7%) | <0.001 |
Stay at home when feeling flu-like symptoms | 3464 (84.0%) | 3418 (72.7%) | 3353 (73.8%) | <0.001 |
Travelled during the past 7 days | 217 (5.3%) | 827 (17.6%) | 640 (14.1%) | <0.001 |
Adherence score category: | <0.001 | |||
0 | 193 (4.7%) | 286 (6.1%) | 279 (6.1%) | |
1 | 454 (11.0%) | 639 (13.6%) | 545 (12.0%) | |
2 | 728 (17.7%) | 887 (18.9%) | 915 (20.1%) | |
3 | 1134 (27.5%) | 990 (21.1%) | 998 (22.0%) | |
4 | 1615 (39.2%) | 1901 (40.4%) | 1806 (39.8%) | |
Willing to receive COVID-19 vaccine | 3488 (76.8%) | NA | ||
Reasons for COVID-19 vaccine refusal * | NA | |||
(N = 1055 respondents who were unwilling) | ||||
Vaccine is ineffective | 283 (26.8%) | |||
Fear of side-effects | 424 (40.2%) | |||
COVID-19 is over, no need for vaccine | 308 (29.2%) | |||
My immune system is already very strong | 204 (19.3%) | |||
Other reasons ** | 29 (2.7%) |
* Many responses possible for each participant. ** See details in Supplementary File S2.